MKI67 and cancer: Several recent studies have demonstrated that higher Ki67 proliferative activity was associated with poorer prognosis with respect to recurrence-free survival [28], [29], [30], [31], cancer-specific survival [30], [32], [33], and clinical response to chemotherapy [28], [34].